After months of delay in its decision, the FDA has given a green light to Pfizer and Myovant’s drug Myfembree for pain related endometriosis, a gynecological condition associated with moderate to severe pain, making it the drug’s second indication approval.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,